Company Research Report: IAVI (International AIDS Vaccine Initiative)
Company Overview
- Name: International AIDS Vaccine Initiative (IAVI)
- Mission: To translate scientific discoveries into affordable, globally accessible public health solutions.
- Vision: A world where all people have equitable access to innovative vaccines and therapeutics.
- Founded: 1996
- Founders: Conceived by 24 authorities on HIV/AIDS at a meeting convened by The Rockefeller Foundation.
- Key People:
- Mark Feinberg, President & CEO
- Swati Gupta, Vice President, Emerging Infectious Diseases & Scientific Strategy
- Linda-Gail Bekker, Board Member
- Ansuya Naidoo, Medical Director, Clinical Development
- Headquarters: 125 Broad Street, 9th Floor, New York, NY 10004, USA
- Number of Employees: 350+ employees across 4 continents and more than 8 countries
- Revenue: $128M in 2022
- Known For: Developing vaccines and antibodies for HIV, tuberculosis, and emerging infectious diseases
Products
- Vaccines and Antibodies for Global Health: IAVI is known for its focus on diseases such as HIV, tuberculosis, and emerging infectious diseases like Lassa fever, Marburg virus, Sudan Ebolavirus, and COVID-19. It pursues a multidisciplinary approach to discovery and development.
- Key Features:
- HIV Vaccines and Antibodies: Development of broadly neutralizing antibodies (bnAbs) and vaccine candidates using advanced technology like mRNA.
- TB Vaccine Candidates: Collaboration with partners like Moderna and Biofabri to develop MTBVAC, the only live, attenuated vaccine candidate derived from M.tb.
- Emerging Infectious Diseases Vaccines: Development of vaccine candidates for Lassa fever, Marburg virus, and other EIDs using the vesicular stomatitis virus (VSV) platform.
Recent Developments
- Recent Partnerships: MOU signed with Africa CDC to enhance vaccine and antibody research capacity in Africa. Participation in ADVANCE and CASPR initiatives to support HIV vaccine development.
- New Product Launches: Ongoing clinical trials for HIV vaccine candidates, including Phase 1 trials using mRNA platforms.
- New Features: Initiatives in developing and testing vaccines that utilize the vesicular stomatitis virus (VSV) platform.
- Public Engagements: Participation in forums like the World Vaccine Congress Europe and the HIV Research for Prevention Conference (HIVR4P).
IAVI continues to innovate in vaccine design, clinical development, and global access efforts, engaging multiple stakeholders to address the world's pressing health challenges.
